Business
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors (Board) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on December 3, 2025. Sutro’s co
About this update from Sutro Biopharma, Inc.
[{"type":"image","alt":"Sutro Biopharma, Inc.","displaySize":"","headline":null,"caption":"Sutro Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":186,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rd31Oc6_ZbJywDRY5HheFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8","width":186,"height":55}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors (Board) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on December 3, 2025. Sutro’s common stock will begin trading on a post-reverse stock split basis on December 3, 2025, under the Company’s existing trading symbol “STRO” with a new CUSIP number of 869367201. The reverse stock split is intended to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share.","length":796,"tagName":"p"},{"type":"text","content":"The reverse stock split was approved by Sutro’s stockholders at the Company’s 2025 annual meeting of stockholders held on June 6, 2025, to be effected at the Board’s discretion within approved parameters. The reverse stock split reduces the number of shares of the Company’s outstanding common stock from approximately 85,193,912 shares to approximately 8,519,392. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Sutro’s common stock underlying the Company’s outstanding equity awards for common stock, as well as the number of shares issuable under the Company’s equity incentive and inducement plans, and employee stock purchase plan. There will be no change to the number of authorized shares or to the par value per share.","length":804,"tagName":"p"},{"type":"text","content":"Information for Sutro’s Stockholders","length":36,"tagName":"p"},{"type":"text","content":"Sutro’s transfer agent, Equiniti Tr...